As PD-1 is the major regulator of T cell exhaustion, together with other inhibitory receptors like CTLA-4 or TIM-3, T cells with high PD-1 expression lose the ability to eliminate cancer, and PD-1+ TILs are therefore associated with poor clinical outcome [45,46,47]. Here, HAVCR2 is linked to cancer.